English Funding Rejections Reversed For Brukinsa, Adtralza, Cibinqo & Rinvoq
Executive Summary
Health technology assessment institute NICE now believes that BeiGene’s drug for Waldenström's macroglobulinemia and three atopic dermatitis treatments, from LEO, Pfizer and AbbVie, are cost-effective.